Cardiovascular Drugs Market Size, Share, Trends, Growth and Forecast 2032

Cardiovascular Drugs Market Insights

According to the report published by Zion Market Research, the global Cardiovascular Drugs Market size was valued at USD 27.29 Billion in 2023 and is predicted to reach USD 35.30 Billion by the end of 2032. The market is expected to grow with a CAGR of 2.9% during the forecast period. The report analyzes the global Cardiovascular Drugs Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Cardiovascular Drugs industry.

Request Free Sample

Global Cardiovascular Drugs Market: Overview

Cardiovascular diseases are popularly known as heart diseases. These diseases are associated with circulatory system and heart. To list a few common cardiovascular diseases—rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease. High blood pressure causes hypertensive heart disease. Key concerns related to hypertensive heart disease are hypertrophy, heart failure, angina, and coronary heart disease. Brain blood vessels get affected by the cerebrovascular disease. Cerebrovascular disease common types are a stroke, vascular dementia, transient ischemic attack, and subarachnoid hemorrhage.

Global Cardiovascular Drugs Market: Growth Factors

The global cardiovascular disease drug market is anticipated to witness a high growth mainly owing to rising incidences of people suffering from cardiovascular disease. Another major factor positively impacting the growth of the global cardiovascular disease drug market is increasing number of diabetes and obese patients. Increasing geriatric population, unhealthy life style, and the existence of numerous novel drugs in the clinical studies are additional factors boosting the growth of the global cardiovascular disease drug market. Drugs development specifically for numerous applications is, on the other hand, major market restraint faced by key players in the global cardiovascular disease drug market.

Request Free Sample

Global Cardiovascular Drugs Market: Segmentation

The global cardiovascular disease drug market is segmented on the basis of disease, drug class, and distribution channel.

Based on the disease, the global market is classified into cardiac arrhythmias, arteriosclerosis, acute coronary syndrome, myocardial infarction, coronary artery disease, peripheral artery disease, hyperlipidaemia, hypertension, cardiac failure diseases, thrombosis, and others.

Based on the drug class, the global cardiovascular disease drug market is diversified as anti-hyperlipidemics, anti-fibrinolytic, anti-hypertensive, anti-arrhythmic, anti-coagulants, and others. The others segment is further sub-segmented as anti-ischemic drugs, anti-anginal drugs, and cardiac glycosides.

Based on the distribution channel, the global cardiovascular disease drug market is classified as hospital pharmacies, retail pharmacies, and online pharmacies.

Cardiovascular Drugs Market: Report Scope

Global Cardiovascular Drugs Market: Regional Analysis

North America is anticipated to dominate the global cardiovascular drugs market in the coming years. The major reason for this growth is rising awareness of numerous heart diseases in this region. Also, the US is expected to witness significant growth in the global cardiovascular drugs market. This trend is flowed by Canada. Moreover, in Europe, the UK, Germany, Italy, France, and Spain grab the major market share. Nevertheless, Asia is anticipated to witness considerable growth in the near future in the global cardiovascular drugs market mainly owing to major players investing R&D facilities in this region.

Global Cardiovascular Drugs Market: Competitive Players

Major players dominating the global cardiovascular disease drug market include:

• Pfizer, Inc.
• AstraZeneca plc
• Merck & Co.
• Sanofi S.A.
• Novartis AG
• Daiichi Sankyo Company Limited
• Takeda Pharmaceutical Company Limited
• Bayer AG.

Other key players influencing the global cardiovascular disease drug market are:

• Astellas Pharma Inc.
• Boehringer Ingelheim GmbH
• United Therapeutics Corporation
• Johnson & Johnson
• Roche Holding AG
• Actelion Pharmaceuticals Ltd.

The Global Cardiovascular Drugs Market is segmented as follows:
 
By Disease 

• cardiac arrhythmias
• arteriosclerosis
• acute coronary syndrome 
• myocardial infarction 
• coronary artery disease 
• peripheral artery disease 
• hyperlipidaemia
• hypertension
• cardiac failure diseases 
• thrombosis
• and others

By Drug class 

• anti-hyperlipidemics 
• anti-fibrinolytic 
• anti-hypertensive
• anti-arrhythmic
• anti-coagulants
• and others

By Distribution channel 

• hospital pharmacies
• retail pharmacies
• online pharmacies

Global Cardiovascular Drugs Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • The UK
  • France
  • Germany
• The Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.